Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis

References

• Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Arthritis Rheum. 1995;38(11):1535–1540. doi:10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Osteoarthritis: care and management. In: NICE Clinical Guideline 177. 2014.
   Google Scholar
• Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2004;64(5):669–681. doi:10.1136/ard.2004.028886
   Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–162. doi:10.1016/j.joca.2007.12.013
   PubMed Web of Science ®Google Scholar
• Pairet M, Van Ryn J. COX-2 Inhibitors. Birkhäuser; 2012.
   Google Scholar
• Chan FKL, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173–179. doi:10.1016/S0140-6736(10)60673-3
   PubMed Web of Science ®Google Scholar
• Collaboration CatNTC, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (London, England). 2013;382(9894):769–779.
   Web of Science ®Google Scholar
• Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 2013;108(3):392–400. doi:10.1038/ajg.2012.467
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375:2519–2529. doi:10.1056/NEJMoa1611593
   PubMed Web of Science ®Google Scholar
• Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017;130(12):1415–1422.e1414. doi:10.1016/j.amjmed.2017.06.028
   PubMed Web of Science ®Google Scholar
• Essex M, Bhadra P, Sands G. Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial. J Int Med Res. 2012;40(4):1357–1370. doi:10.1177/147323001204000414
   Web of Science ®Google Scholar
• Pfizer I CELEBREX – celecoxib capsule. 2015. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=793. Accessed December 12, 2015.
   Google Scholar
• Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015;13:55. doi:10.1186/s12916-015-0285-8
   PubMed Web of Science ®Google Scholar
• Gore M, Sadosky A, Leslie D, Tai K-S, Seleznick M. Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther. 2011;33(12):1914–1931. doi:10.1016/j.clinthera.2011.10.019
   PubMed Web of Science ®Google Scholar
• Gore M, Sadosky AB, Leslie DL, Tai K-S, Emery P. Therapy switching, augmentation, and discontinuation in patients with osteoarthritis and chronic low back pain. Pain Pract. 2012;12(6):457–468. doi:10.1111/ppr.2012.12.issue-6
   PubMed Web of Science ®Google Scholar
• Zhao SZ, Wentworth C, Burke TA, Makuch RW. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf. 2004;13(5):277–287. doi:10.1002/(ISSN)1099-1557
   Web of Science ®Google Scholar
• Hansen LG, Chang S. White Paper – Health Research Data for the Real World: The MarketScan Databases. Cambridge, MA: Thomson Medstat; 2011.
   Google Scholar
• Sinusas K. Osteoarthritis: diagnosis and treatment. Am Fam Physician. 2012;85(1):49–56.
   PubMed Web of Science ®Google Scholar
• Administration FaD. Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Available from: https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm106241.pdf. Accessed February 14, 2018.
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452
   Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150–161. doi:10.1002/pst.v10.2
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39(1):33–38.
   Web of Science ®Google Scholar
• Dunn JD, Pill MW. A claims-based view of health care charges and utilization for commercially insured patients with osteoarthritis. Managed Care (Langhorne, PA). 2009;18(12):44–50.
   PubMedGoogle Scholar
• Le KT, Montejano LB, Cao Z, Zhao Y, Ang D. Healthcare costs associated with osteoarthritis in US patients. Pain Pract. 2012;12(8):633–640. doi:10.1111/j.1533-2500.2012.00535.x
   PubMed Web of Science ®Google Scholar
• Shelbaya A, Solem CT, Walker C, Wan Y, Johnson C, Cappelleri JC. The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis. CEOR. 2018;10:213–222. doi:10.2147/CEOR.S140208
   Web of Science ®Google Scholar
• Huelin R, Pokora T, Foster TS, Mould JF. Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):505–523. doi:10.1586/erp.12.36
   PubMed Web of Science ®Google Scholar